PacBio Expands Partnership with seqWell to Bring Scalable Long Read Sample Prep to More Labs
PacBio (NASDAQ: PACB) expanded its partnership with seqWell to distribute the LongPlex™ Multiplexing Kit, a scalable sample-prep solution optimized for PacBio HiFi sequencing. The kit uses tagmentation to fragment and index DNA, supporting multiplexing of up to hundreds of samples per run and workflows including low-pass whole genome sequencing, plasmid resequencing, and microbial sequencing. The LongPlex kit is available now with global availability in 2026, and is positioned to reduce hands-on time and cost per sample for high-throughput projects.
PacBio (NASDAQ: PACB) ha ampliato la sua partnership con seqWell per distribuire il LongPlex™ Multiplexing Kit, una soluzione di preparazione campione scalabile ottimizzata per il sequenziamento PacBio HiFi. Il kit utilizza la tagmentazione per frammentare e indicizzare il DNA, supportando il multiplexing di fino a centinaia di campioni per run e flussi di lavoro tra cui sequencing a bassa copertura dell’intero genoma, rifusione dei plasmidi e sequenziamento microbiano. Il kit LongPlex è ora disponibile con disponibilità globale nel 2026, ed è progettato per ridurre il tempo di lavoro pratico e il costo per campione per progetti ad alto rendimento.
PacBio (NASDAQ: PACB) expandió su asociación con seqWell para distribuir el LongPlex™ Multiplexing Kit, una solución de preparación de muestras escalable optimizada para la secuenciación HiFi de PacBio. El kit utiliza tagmentación para fragmentar e indexar el ADN, soportando multiplexar hasta cientos de muestras por corrida y flujos de trabajo que incluyen secuenciación de genoma completo a baja cobertura, resecuenciación de plásmidos y secuenciación microbiana. El kit LongPlex ya está disponible con disponibilidad global en 2026, y está diseñado para reducir el tiempo de manejo y el costo por muestra para proyectos de alto rendimiento.
PacBio (NASDAQ: PACB)가 seqWell과의 파트너십을 확장하여 LongPlex™ Multiplexing Kit를 배포합니다. 이는 PacBio HiFi 시퀀싱에 최적화된 확장 가능한 샘플 준비 솔루션입니다. 이 키트는 DNA를 태그멘테이션으로 분해하고 인덱싱하며, 한 번의 실행에 수백 개의 샘플을 멀티플렉싱하는 것을 지원하고, 저선량 전장 게놈 시퀀싱, 플라스미드 재시퀀싱, 미생물 시퀀싱 등의 워크플로를 포함합니다. LongPlex 키트는 현재 이용 가능하며 전 세계 이용 가능 2026년에 출시될 예정이며, 대량 고처리 프로젝트의 수고 시간과 샘플당 비용을 줄이도록 설계되었습니다.
PacBio (NASDAQ : PACB) a étendu son partenariat avec seqWell pour distribuer le LongPlex™ Multiplexing Kit, une solution de préparation d'échantillons évolutive optimisée pour le séquençage PacBio HiFi. Le kit utilise la tagmentation pour fragmenter et indexer l'ADN, prenant en charge le multiplexage de centaines d'échantillons par exécution et des flux de travail comprenant le séquençage du génome entier à faible couverture, le resequencing de plasmides et le séquençage microbien. Le kit LongPlex est désormais disponible avec une disponibilité mondiale en 2026, et il est conçu pour réduire le temps de manipulation et le coût par échantillon pour les projets à haut débit.
PacBio (NASDAQ: PACB) hat seine Partnerschaft mit seqWell erweitert, um das LongPlex™ Multiplexing Kit zu vertreiben, eine skalierbare Probenvorbereitungslösung, optimiert für PacBio HiFi-Sequenzierung. Das Kit nutzt die Tagmentierung, um DNA zu fragmentieren und zu indizieren, unterstützt das Multiplexing von bis zu Hunderten von Proben pro Lauf und Workflows einschließlich Low-Pass-Whole-Genome-Sequencing, Plasmid-Resequenzierung und mikrobiellem Sequencing. Das LongPlex-Kit ist jetzt verfügbar mit globaler Verfügbarkeit 2026 und soll dazu beitragen, die manuelle Arbeitszeit und die Kosten pro Probe für Hochdurchsatzprojekte zu reduzieren.
PacBio (المدرَج في ناسداك: PACB) وسّعت شراكتها مع seqWell لتوزيع LongPlex™ Multiplexing Kit، وهو حل تجهيز عيّنات قابل للتوسع ومُموَّل لتحسين تسلسل PacBio HiFi. يستخدم الكيت تقنية التاغمنتاشن لتجزئة وترميز الحمض النووي DNA، ويدعم التعدد في العينات حتى مئات العينات في كل تشغيل وعمليات تدفق عمل تشمل تسلسل الجينوم الكامل منخفض التغطية، وإعادة تسلسل البلازميدات، وتسلسل الميكروبات. يتوفر Kit LongPlex الآن مع توفر عالمي في 2026، وهو مُصمَّم لخفض وقت العمل اليدوي وتكلفة العينة لمشروعات عالية الإنتاجية.
PacBio（纳斯达克：PACB） 与 seqWell 的合作关系扩大，以分发 LongPlex™ Multiplexing Kit，这是一种可扩展的样品制备解决方案，针对 PacBio HiFi 测序进行了优化。该套件使用 tagmentation 将 DNA 片段化并进行索引，支持每次运行对多达数百个样本的多重测序，并涵盖低覆盖度全基因组测序、质粒重新测序和微生物测序等工作流程。LongPlex 套件现已上市，全球供应将于 2026 年提供，旨在降低高通量项目的人工作业时间和每个样本的成本。
- Adds scalable LongPlex distribution to PacBio product portfolio
- Supports multiplexing of up to hundreds of samples per run
- Targets low-pass WGS, plasmid, and microbial sequencing workflows
- Available now with global availability in 2026
- No financial or commercial terms disclosed in the announcement
- Full global availability not expected until 2026
Insights
Expanded distribution of seqWell's LongPlex by PacBio increases high-throughput sample‑prep options and supports scaling of HiFi workflows.
PacBio will distribute seqWell's LongPlex™ Multiplexing Kit to complement its HiFi sequencing workflows, enabling tagmentation-based fragmentation and indexing for hundreds of samples per run. The kit targets low-pass whole genome sequencing, plasmid resequencing, and microbial sequencing and aims to reduce hands-on time while preserving library quality.
Key dependencies and risks include real-world adoption rates, operational integration into existing pipelines, and the stated timeline for wider availability in
Watch for distribution milestones, uptake in high-throughput projects, and any published performance comparisons with existing PacBio prep options over the next 6–18 months; broader commercial availability is scheduled for
Highly scalable, cost-effective LongPlex™ kit delivers streamlined tagmentation and multiplexing for low-pass whole genome sequencing, plasmid resequencing, and microbial sequencing
MENLO PARK, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced an expanded partnership with seqWell, a global provider of genomic library and multiplexing workflow solutions. Under the new agreement, PacBio will distribute seqWell’s LongPlex™ Multiplexing Kit, a scalable, easy-to-use sample preparation solution designed for use with PacBio HiFi sequencing and optimized for efficient transposase-based DNA fragmentation and multiplexing. LongPlex removes sample prep bottlenecks, enabling researchers to produce high-quality libraries quickly, support current studies cost-efficiently, and power the next wave of population-scale research.
This collaboration expands the portfolio of workflow options available to PacBio customers, complementing PacBio’s highly accurate long-long read technology with an additional flexible, high-throughput sample prep solution. The LongPlex™ Multiplexing Kit uses tagmentation to simultaneously fragment and index DNA for up to hundreds of samples in a single run, making it ideal for large-scale screening and targeted resequencing efforts.
“Expanding our partnership with seqWell is part of our commitment to meet researchers where they are with the flexibility, speed, and accuracy they need,” said David Miller, Vice President of Global Marketing at PacBio. “By offering LongPlex alongside our existing workflows, we’re giving customers more choice across high-throughput applications, especially where rapid, economical data generation is essential.”
Organizations such as Veil Genomics are already demonstrating the value of LongPlex for population-scale efforts.
“At Veil, our goal is to democratize genomic insights through scalable, cost-effective data,” said Josh Clevenger, Ph.D., Co-founder of Veil Genomics. “The LongPlex™ Multiplexing Kit has allowed us to continue to develop our low-pass WGS workflow, supporting efficient DNA fragmentation and multiplexing that let us process thousands of samples without compromising data quality for downstream analysis.”
By supporting sample prep across low-pass WGS, plasmid sequencing, and microbial sequencing, LongPlex extends options for researchers working in diverse fields. Its streamlined indexed tagmentation workflow reduces hands-on time while maintaining the performance required for high-quality sequencing data.
“We’re proud to expand our collaboration with PacBio, bringing LongPlex™ to more labs worldwide,” said Dan Calvo, President and CEO of seqWell. “This agreement reflects a shared vision to accelerate discovery by making innovative, practical sample prep tools widely available to genomic researchers.”
The LongPlex™ Multiplexing Kit is available today, with global availability in 2026, adding a scalable sample prep option to PacBio’s portfolio of sequencing solutions.
For more information about the LongPlex™ Multiplexing Kit and compatible workflows, please visit www.pacb.com.
About PacBio
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
About seqWell
seqWell creates scalable genomics technologies that simplify library preparation workflows and help scientists to unlock transformative discoveries with sequencing. seqWell offers a range of library prep products and tagmentation workflows designed to meet the throughput and cost demands of modern genomics applications including population-scale, short- and long-read sequencing initiatives. Learn more at www.seqwell.com or follow us on Linkedin.
About Veil Genomics
Veil Genomics is a precision genomics company dedicated to population-scale low-pass WGS and data-driven insights for health and agriculture. By combining innovative sequencing pipelines with powerful analytics, Veil delivers actionable genomic information to drive real-world impact.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, advantages, or quality or performance of, or benefits or expected benefits of using, PacBio products or technologies, such as those in connection with seqWell’s LongPlex Multiplexing Kit, expanding sample prep and workflow options, and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, challenges inherent in new collaborations; the difficulty of generating discoveries across various areas of research; potential product performance and quality issues; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; and other risks associated with international operations. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8- K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
Contacts (PacBio)
Investors:
Media: pr@pacificbiosciences.com
FAQ
What did PacBio (PACB) announce on October 7, 2025 about seqWell?
How many samples can seqWell LongPlex multiplex for PacBio HiFi sequencing?
When will the LongPlex Multiplexing Kit be available globally for PACB customers?
Which sequencing workflows does LongPlex support with PacBio HiFi?
What operational benefits does LongPlex offer PacBio users?
Will the PacBio and seqWell agreement include pricing or revenue details for PACB investors?
